Shares of XOMA Co. (NASDAQ:XOMA – Get Free Report) crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $16.72 and traded as high as $17.00. XOMA shares last traded at $15.86, with a volume of 17,854 shares changing hands.
Analysts Set New Price Targets
A number of analysts recently issued reports on XOMA shares. HC Wainwright reissued a “buy” rating and set a $74.00 price target on shares of XOMA in a report on Wednesday, September 13th. StockNews.com began coverage on XOMA in a report on Thursday, October 5th. They issued a “sell” rating on the stock.
XOMA Trading Up 7.9 %
XOMA (NASDAQ:XOMA – Get Free Report) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.12). The firm had revenue of $0.83 million for the quarter, compared to analysts’ expectations of $1.47 million. XOMA had a negative return on equity of 24.70% and a negative net margin of 636.27%. On average, analysts predict that XOMA Co. will post -2.05 earnings per share for the current year.
Hedge Funds Weigh In On XOMA
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Stonepine Capital Management LLC lifted its stake in XOMA by 25.0% in the 3rd quarter. Stonepine Capital Management LLC now owns 436,602 shares of the biotechnology company’s stock worth $6,152,000 after purchasing an additional 87,203 shares in the last quarter. Northern Trust Corp boosted its stake in XOMA by 1.3% during the third quarter. Northern Trust Corp now owns 87,208 shares of the biotechnology company’s stock worth $1,229,000 after buying an additional 1,133 shares during the last quarter. Barclays PLC purchased a new stake in XOMA in the 2nd quarter valued at $28,000. California State Teachers Retirement System purchased a new stake in XOMA in the 2nd quarter valued at $46,000. Finally, Wells Fargo & Company MN increased its stake in shares of XOMA by 1,120.9% in the 2nd quarter. Wells Fargo & Company MN now owns 2,979 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 2,735 shares during the last quarter. 65.35% of the stock is currently owned by institutional investors and hedge funds.
XOMA Corporation operates as a biotech royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.
- Five stocks we like better than XOMA
- Most active stocks: Dollar volume vs share volume
- 3 large caps with red hot RSIs with upside
- How to Calculate Inflation Rate
- Johnson Controls International: Nothing but upside for investors
- What is the Nikkei 225 index?
- Unity Software’s resilient rebound post-earnings setback
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.